This is why, at Roche, we are pursuing the immense challenges of neuroscience with curiosity, passion and rigour. Our research efforts are contributing to promising changes in the landscape of treatments for neurological disorders and MS – with newer medicines for MS showing that earlier initiation and continuation of treatment can reduce disability progression over a sustained period of time.

We have one of the most advanced neuroscience pipelines in the industry, with six late-stage investigational medicines in development, spanning the spectrum of nervous system disorders from the rarest to the most common – for conditions that include multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and autism.